Drug-Primed Self-Assembly of Platinum-Single-Atom Nanozyme to Regulate Cellular Redox Homeostasis Against Cancer

Adv Sci (Weinh). 2023 Oct;10(30):e2302703. doi: 10.1002/advs.202302703. Epub 2023 Sep 11.

Abstract

Single-atom nanozymes (SAzymes) with high catalytic activity exhibit the potential to disequilibrate the reactive oxygen metabolic balance in the tumor microenvironment (TME), which contains several endogenous reductive substances such as glutathione (GSH). Herein, a novel nano-assembly (CDs@Pt SAs/NCs@DOX) is first constructed using drug-primed platinum (Pt) single-atom or nanocluster nanozymes with a Pt loading of 34.8%, which exhibits prominent dual enzymatic activities to mimic peroxidase (POD) and glutathione oxidase (GSHOx). The unique GSHOx-like activity can efficiently scavenge GSH with a relatively low Km (1.04 mm) and high Vmax (7.46 × 10-6 m s-1 ), thus avoiding single oxygen (1 O2 ) depletion. CDs@Pt SAs/NCs@DOX simultaneously demonstrates low-temperature photothermal therapy and TME- or laser-controlled disassembly and drug release, which can effectively regulate cellular redox homeostasis and achieve high tumor growth inhibition. These outcomes may provide promising strategies for the preparation of Pt SAzymes with multiple activities and variable-sized nano-assemblies, allowing for broader applications of SAzymes and nano-assemblies in the biomedical field.

Keywords: carbon dots; cellular homeostasis; platinum; self-assembly; single-atom nanozymes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Glutathione
  • Homeostasis
  • Humans
  • Neoplasms* / drug therapy
  • Oxidation-Reduction
  • Oxygen
  • Platinum*
  • Tumor Microenvironment

Substances

  • Platinum
  • Glutathione
  • Oxygen